CA
LUCD icon

Clearstead Advisors’s Lucid Diagnostics LUCD Stock Holding History

Clearstead Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95 Buy
+88
New +$95 ﹤0.01% 3366
2025
Q4 		– Sell
-1
Closed -$2 – 3048
2025
Q3 		$2 Buy
+1
New +$1 ﹤0.01% 3081

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Clearstead Advisors's LUCD Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 88 shares worth $95. The stake represents ﹤0.01% of the portfolio and ranks #3366 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in LUCD as recently as Q3 2025.

Clearstead Advisors first reported a position in LUCD in Q3 2025 and has held it in 2 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Clearstead Advisors held 88 shares of Lucid Diagnostics worth $95 as of Q2 2026.
  • Lucid Diagnostics was a new Clearstead Advisors position in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3366 holding.
  • Clearstead Advisors first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 2 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.